• Régis Peffault de Latour, Claudio G Brunstein, Raphael Porcher, Patrice Chevallier, Marie Robin, Erica Warlick, Alienor Xhaard, Celalettin Ustun, Jérôme Larghero, Nathalie Dhedin, Mohamad Mohty, Gerard Socié, and Daniel Weisdorf.
• Service d'Hématologie Greffe, Hôpital Saint-Louis, AP HP, Paris, France; Equipe d'accueil 3518, Hôpital Saint-Louis & Université Paris 7, AP-HP, Paris, France. regis.peffaultdelatour@sls.aphp.fr
• Biol. Blood Marrow Transplant. 2013 Sep 1; 19 (9): 1355-60.

AbstractFor older patients with acute myeloid leukemia (AML), allogeneic hematopoietic cell transplantation (HCT) provides the best chance of long-term survival. A formal comparison between matched sibling (SIB), unrelated donor (URD), or umbilical cord blood (UCB) transplantation has not yet been reported in this setting. We compared reduced-intensity conditioning HCT in 197 consecutive patients 50 years and older with AML in complete remission from SIB (n = 82), URD (n = 35), or UCB (n = 80) transplantation. The 3-year cumulative incidences of transplantation-related mortality were 18%, 14%, and 24% with SIB, URD, and UCB transplantation, respectively (P = .22). The 3-year leukemia-free survival rates were 48%, 57%, and 33% with SIB, URD, and UCB transplantation, respectively (P = .009). In multivariate analysis, poor-risk cytogenetics was associated with relapse (hazard ratio, 1.7 [95% confidence interval, 1.0 to 3.0]; P = .04) and worse leukemia-free survival (hazard ratio, 1.6 [95% confidence interval, 1.0 to 2.5]; P = .03), whereas donor choice had no significant impact on overall survival (P = .73). Adjusted 3-year overall survival rates were 55% with SIB, 45% with URD, and 43% with UCB transplantation (P = .26). Until prospective studies are completed, this study supports the recommendation to consider SIB donor, URD, or UCB for HCT for older patients with AML in complete remission.Copyright © 2013 American Society for Blood and Marrow Transplantation. All rights reserved.

24 keywords...

hide…